Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reports that several senior leaders and one person closely associated with a leader acquired small amounts of company stock through its Share Reward Plan. On 2026-06-09, each transaction involved GSK ordinary shares of 31 ¼ pence each, traded on the London Stock Exchange.
Executives including President Europe Lynn Baxter, Chief Financial Officer Julie Brown, and other senior leaders acquired either 14 or 12 ordinary shares each at a price of £18.8393 per share, split between partnership and matching shares. These are routine share plan acquisitions rather than open-market trades.
GSK plc reports that several senior leaders and one person closely associated with a leader acquired small amounts of company stock through its Share Reward Plan. On 2026-06-09, each transaction involved GSK ordinary shares of 31 ¼ pence each, traded on the London Stock Exchange.
Executives including President Europe Lynn Baxter, Chief Financial Officer Julie Brown, and other senior leaders acquired either 14 or 12 ordinary shares each at a price of £18.8393 per share, split between partnership and matching shares. These are routine share plan acquisitions rather than open-market trades.
GSK plc reported that Maya Martinez-Davis, President, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction involved 9.4289 ADS at a price of $50.6400 per ADS on 2026-06-08, executed on the New York Stock Exchange.
GSK plc reported that Maya Martinez-Davis, President, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction involved 9.4289 ADS at a price of $50.6400 per ADS on 2026-06-08, executed on the New York Stock Exchange.
GSK plc reported a change in the outside roles of one of its board members. Dr Hal Barron, a Non-Executive Director at GSK, was appointed an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. on 4 June 2026.
The company notes this appointment in line with UK Listing Rule 6.4.9R(2). GSK remains a global biopharma company focused on uniting science, technology and talent to get ahead of disease.
GSK plc reported a change in the outside roles of one of its board members. Dr Hal Barron, a Non-Executive Director at GSK, was appointed an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. on 4 June 2026.
The company notes this appointment in line with UK Listing Rule 6.4.9R(2). GSK remains a global biopharma company focused on uniting science, technology and talent to get ahead of disease.
GSK plc plans to acquire US oncology company Nuvalent, Inc. in a cash deal valuing the target at $10.6 billion. GSK will launch a tender offer at $124 per share, a 40% premium to Nuvalent’s last closing price and 26% above its 30‑day VWAP.
The transaction adds three lung cancer drugs, including two late‑stage ROS1 and ALK inhibitors under US FDA review with 2026 target decision dates, plus a HER2 inhibitor in phase I. GSK expects low single‑digit core EPS dilution through 2028, accretion to core operating profit in 2027 and to core EPS in 2029, while maintaining 2026 guidance and a 70p dividend.
GSK plc plans to acquire US oncology company Nuvalent, Inc. in a cash deal valuing the target at $10.6 billion. GSK will launch a tender offer at $124 per share, a 40% premium to Nuvalent’s last closing price and 26% above its 30‑day VWAP.
The transaction adds three lung cancer drugs, including two late‑stage ROS1 and ALK inhibitors under US FDA review with 2026 target decision dates, plus a HER2 inhibitor in phase I. GSK expects low single‑digit core EPS dilution through 2028, accretion to core operating profit in 2027 and to core EPS in 2029, while maintaining 2026 guidance and a 70p dividend.
GSK plc reports further repurchases of its ordinary shares between 1 and 5 June 2026 as part of its existing buyback programme, executed through Citigroup Global Markets Limited. Daily buybacks ranged from 217,096 to 496,356 shares, with volume-weighted average prices between 1,824.85 GBp and 1,922.23 GBp per share.
Since 11 May 2026 the company has purchased 6,233,812 ordinary shares. After the latest transactions, GSK holds 267,612,098 ordinary shares in treasury and has 4,048,628,915 ordinary shares in issue, giving the same number of total voting rights. Treasury shares represent 6.61% of voting rights, a figure shareholders can use when assessing disclosure thresholds.
GSK plc reports further repurchases of its ordinary shares between 1 and 5 June 2026 as part of its existing buyback programme, executed through Citigroup Global Markets Limited. Daily buybacks ranged from 217,096 to 496,356 shares, with volume-weighted average prices between 1,824.85 GBp and 1,922.23 GBp per share.
Since 11 May 2026 the company has purchased 6,233,812 ordinary shares. After the latest transactions, GSK holds 267,612,098 ordinary shares in treasury and has 4,048,628,915 ordinary shares in issue, giving the same number of total voting rights. Treasury shares represent 6.61% of voting rights, a figure shareholders can use when assessing disclosure thresholds.
GSK plc reported its total voting rights as of 31 May 2026. The company’s issued share capital consisted of 4,316,224,814 ordinary shares of 31 ¼ pence each, of which 265,968,706 were held in treasury. This leaves 4,050,256,108 voting rights currently in issue.
Shareholders can use this voting rights figure as the denominator when calculating whether they must notify the company and regulators about their shareholdings or changes in their interests under the UK Financial Conduct Authority’s disclosure rules.
GSK plc reported its total voting rights as of 31 May 2026. The company’s issued share capital consisted of 4,316,224,814 ordinary shares of 31 ¼ pence each, of which 265,968,706 were held in treasury. This leaves 4,050,256,108 voting rights currently in issue.
Shareholders can use this voting rights figure as the denominator when calculating whether they must notify the company and regulators about their shareholdings or changes in their interests under the UK Financial Conduct Authority’s disclosure rules.
GSK plc reports that, under its existing share buyback programme, it repurchased ordinary shares of 31¼ pence each on 26–29 May 2026 through Citigroup Global Markets Limited. Daily purchases ranged from 301,200 to 319,949 shares, at volume weighted average prices between 1,899.95 and 1,932.82 GBp per share.
The repurchased shares will be held as treasury shares. Since 11 May 2026 the company has bought 4,590,420 ordinary shares. After these transactions, GSK holds 265,968,706 ordinary shares in treasury and has 4,050,256,108 ordinary shares in issue, which is also the total number of voting rights, with 6.57 per cent of voting rights attributable to treasury shares.
GSK plc reports that, under its existing share buyback programme, it repurchased ordinary shares of 31¼ pence each on 26–29 May 2026 through Citigroup Global Markets Limited. Daily purchases ranged from 301,200 to 319,949 shares, at volume weighted average prices between 1,899.95 and 1,932.82 GBp per share.
The repurchased shares will be held as treasury shares. Since 11 May 2026 the company has bought 4,590,420 ordinary shares. After these transactions, GSK holds 265,968,706 ordinary shares in treasury and has 4,050,256,108 ordinary shares in issue, which is also the total number of voting rights, with 6.57 per cent of voting rights attributable to treasury shares.
GSK reports pivotal Phase III results showing its investigational hepatitis B therapy bepirovirsen achieved markedly higher functional cure rates than current treatments. In pooled B‑Well 1 and 2 trials, 6‑month bepirovirsen plus standard of care produced a 19% functional cure in adults with baseline HBsAg ≤3000 IU/mL, versus 0% with standard care alone.
Among participants with baseline HBsAg ≤1000 IU/mL, who represent a large share of diagnosed cases, the functional cure rate reached 26% versus 0% on placebo. An exploratory analysis found 49% of bepirovirsen recipients had qHBsAg ≤100 IU/mL one year after treatment ended, a level associated with stronger immune control.
Bepirovirsen also delivered sustained HBV DNA suppression in 23% of all treated participants and 31% of those starting with HBsAg ≤1000 IU/mL, with safety generally characterized by injection‑site reactions and transient liver enzyme elevations. The drug is under priority review in the US and other major markets, with first regulatory decisions expected in Q3 2026.
GSK reports pivotal Phase III results showing its investigational hepatitis B therapy bepirovirsen achieved markedly higher functional cure rates than current treatments. In pooled B‑Well 1 and 2 trials, 6‑month bepirovirsen plus standard of care produced a 19% functional cure in adults with baseline HBsAg ≤3000 IU/mL, versus 0% with standard care alone.
Among participants with baseline HBsAg ≤1000 IU/mL, who represent a large share of diagnosed cases, the functional cure rate reached 26% versus 0% on placebo. An exploratory analysis found 49% of bepirovirsen recipients had qHBsAg ≤100 IU/mL one year after treatment ended, a level associated with stronger immune control.
Bepirovirsen also delivered sustained HBV DNA suppression in 23% of all treated participants and 31% of those starting with HBsAg ≤1000 IU/mL, with safety generally characterized by injection‑site reactions and transient liver enzyme elevations. The drug is under priority review in the US and other major markets, with first regulatory decisions expected in Q3 2026.
GSK plc reported an insider transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares (ADS) through her GSK Executive Supplemental Savings Plan account. The plan credited 9.293 ADS at a price of $51.3800 per ADS on May 22, 2026, with the transaction executed on the New York Stock Exchange.
GSK plc reported an insider transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares (ADS) through her GSK Executive Supplemental Savings Plan account. The plan credited 9.293 ADS at a price of $51.3800 per ADS on May 22, 2026, with the transaction executed on the New York Stock Exchange.
GSK plc has admitted a further 45,273 ordinary shares of 31¼ pence each to trading on the London Stock Exchange Main Market. These shares were issued under existing block listing admissions for the “GlaxoSmithKline plc Share Save Plan 2022”. Following this admission, a total of 4,316,221,551 GSK ordinary shares are admitted to trading, and the new shares are fully fungible with existing ordinary shares.
GSK plc has admitted a further 45,273 ordinary shares of 31¼ pence each to trading on the London Stock Exchange Main Market. These shares were issued under existing block listing admissions for the “GlaxoSmithKline plc Share Save Plan 2022”. Following this admission, a total of 4,316,221,551 GSK ordinary shares are admitted to trading, and the new shares are fully fungible with existing ordinary shares.